To be mentioned, there are also many trials which focus on the evaluation of TGF-β inhibitors for cancer therapy, including small molecular antagonist targeting intracellular kinase, neutralization antibody blocking endogenous TGF-β or TGF-β receptor, TGF-β or TGF-β receptor silence or knock-out, and unique disruptors for TGF-β-TGF-β receptor ligation [35–37]. Here, TGFB1 is linked to cancer.